

TRACTATENBLAD

VAN HET

KONINKRIJK DER NEDERLANDEN

JAARGANG 2014 Nr. 162

A. TITEL

*Overeenkomst ter bestrijding van doping;
(met Bijlage)
Straatsburg, 16 november 1989*

B. TEKST

De Engelse en de Franse tekst van de Overeenkomst, met Bijlage, zijn geplaatst in *Trb.* 1991, 8.

In dat Tractatenblad dienen in de Engelse tekst de volgende correcties te worden aangebracht.

Op blz. 6, in artikel 3, tweede lid, vijfde regel, dient het woord „oratisation” te worden vervangen door „organisation”.

Op blz. 18, in artikel 14, tweede lid, tweede regel, dient het woord „desposited” te worden vervangen door „deposited”.

Voor wijzigingen van de tekst van de Bijlage, zie rubriek J van *Trb.* 1995, 114, *Trb.* 1996, 284, *Trb.* 1997, 44, *Trb.* 1997, 244, *Trb.* 1998, 104, *Trb.* 2001, 98, *Trb.* 2001, 185, *Trb.* 2003, 40, *Trb.* 2004, 194 en rubriek B van *Trb.* 2005, 67, *Trb.* 2006, 33, *Trb.* 2008, 83, *Trb.* 2009, 24, *Trb.* 2010, 80, *Trb.* 2011, 19, *Trb.* 2011, 274, *Trb.* 2012, 243 en *Trb.* 2014, 21.

Voor enkele correcties zie *Trb.* 2008, 83 en *Trb.* 2009, 24.

De Commissie van Toezicht heeft tijdens haar 40^{ste} Vergadering op 7 mei 2014, op grond van artikel 11, eerste lid, onder b, van de Overeenkomst, te Straatsburg een wijziging van de Bijlage aangenomen. De Engelse tekst¹⁾ van de wijziging luidt als volgt:

¹⁾ De Franse tekst is niet opgenomen.

The 2014 prohibited list World Anti-Doping Code
Date of entry into force: 1 September 2014

In accordance with Article 4.2.2 of the World Anti-Doping Code, all *Prohibited Substances* shall be considered as “Specified Substances” except Substances in classes S1, S2, S.4.4, S.4.5, S6.a, and *Prohibited Methods* M1, M2 and M3.

Substances and methods prohibited at all times
(in- and out-of-competition)

Prohibited substances

S0. Non-approved substances

Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times.

S1. Anabolic agents

Anabolic agents are prohibited.

1. Anabolic Androgenic Steroids (AAS)

a. Exogenous²⁾ AAS, including:

1-androstenediol (5 α -androst-1-ene-3 β ,17 β -diol);
 1-androstenedione (5 α -androst-1-ene-3,17-dione); bolandiol (estr-4-ene-3 β , 17 β -diol); bolasterone; boldenone; boldione (androsta-1,4-diene-3,17-dione); calusterone; clostebol; danazol ([1,2]oxazolo[4',5':2,3]pregna-4-en-20-yn-17 α -ol); dehydrochloromethyltestosterone (4-chloro-17 β -hydroxy-17 α -methylandrosta-1,4-dien-3-one); desoxymethyltestosterone (17 α -methyl-5 α -androst-2-en-17 β -ol); drostanolone; ethylestrenol (19-norpregna-4-en-17 α -ol); fluoxymesterone; formebolone; furazabol (17 α -methyl[1,2,5]oxadiazolo[3',4':2,3]-5 α -androstan-17 β -ol); gestrinone; 4-hydroxytestosterone (4,17 β -dihydroxyandrost-4-en-3-one); mestanolone; mesterolone; metandienone (17 β -hydroxy-17 α -methylandrosta-1,4-dien-3-one); metenolone; methandriol; methasterone (17 β -hydroxy-2 α ,17 α -dimethyl-5 α -androstan-3-one); methyldienolone (17 β -hydroxy-17 α -methylestra-4,9-dien-3-one); methyl-1-testosterone (17 β -hydroxy-17 α -methyl-5 α -androst-1-en-3-one); methylnortestosterone (17 β -hydroxy-17 α -methylestr-4-en-3-

²⁾ “Exogenous” refers to a substance which is not ordinarily produced by the body naturally.

one); methyltestosterone; metribolone (methyltrienolone, 17 β -hydroxy-17 α -methylene-4,9,11-trien-3-one); mibolerone; nandrolone; 19-norandrostenedione (estr-4-ene-3,17-dione); norbol-
 etone; norclostebol; norethandrolone; oxabolone; oxandrolone; ox-
 ymesterone; oxymetholone; prostanazol (17 β - [(tetrahydropyran-2-
 yl)oxy]-1'H-pyrazolo[3,4:2,3]-5 α -androstane); quinbolone;
 stanazolol; stenbolone; 1- testosterone (17 β -hydroxy-5 α -androst-1-
 en-3-one); tetrahydrogestrinone (17-hydroxyestr-18a-homo-19- nor-
 17 α -pregna-4,9,11-trien-3-one); trenbolone (17 β -hydroxyestr-4,9,11-
 trien-3-one); and other substances with a similar chemical structure or
 similar biological effect(s).

b. Endogenous³⁾ AAS when administered exogenously:

androstenediol (androst-5-ene-3 β ,17 β -diol); androstenedione
 (androst-4-ene-3,17-dione); dihydrotestosterone (17 β -hydroxy-5 α -
 androstan-3-one) ; prasterone (dehydroepiandrosterone, DHEA, 3 β -
 hydroxyandrost-5-en-17-one); testosterone;

and their metabolites and isomers, including but not limited to:

5 α -androstane-3 α ,17 α -diol; 5 α -androstane-3 α ,17 β -diol; 5 α -
 androstane-3 β ,17 α -diol; 5 α -androstane-3 β ,17 β -diol; androst-4-ene-
 3 α ,17 α -diol; androst-4-ene-3 α ,17 β -diol; androst-4-ene-3 β ,17 α -diol;
 androst-5-ene-3 α ,17 α -diol; androst-5-ene-3 α ,17 β -diol; androst-
 5-ene-3 β ,17 α -diol;

4-androstenediol (androst-4-ene-3 β ,17 β -diol);

5-androstenedione (androst-5-ene-3,17-dione); epi-dihydrotestoster-
 one; epitestosterone; etiocholanolone; 3 α -hydroxy-5 α -androstan-17-
 one; 3 β -hydroxy-5 α -androstan-17-one; 7 α -hydroxy-DHEA; 7 β -
 hydroxy-DHEA; 7-keto-DHEA; 19-norandrosterone; 19-
 noretiocholanolone.

2. Other Anabolic Agents, including but not limited to:

Clenbuterol, selective androgen receptor modulators (SARMs),
 tibolone, zeranol, zilpaterol.

S2. Peptide hormones, growth factors and related substances

The following substances, and other substances with similar chemical
 structure or similar biological effect(s), are prohibited:

1. Erythropoiesis-Stimulating Agents [e.g. erythropoietin (EPO), dar-
 bepoetin (dEPO), hypoxia-inducible factor (HIF) stabilizers and activa-
 tors (e.g. xenon, argon), methoxy polyethylene glycol-epoetin beta
 (CERA), peginesatide (Hematide)];

2. Chorionic Gonadotrophin (CG) and Luteinizing Hormone (LH)
 and their releasing factors, in males;

3. Corticotrophins and their releasing factors;

³⁾ "Endogenous" refers to a substance which is ordinarily produced by the
 body naturally.

4. Growth Hormone (GH) and its releasing factors and Insulin-like Growth Factor-1 (IGF-1).

In addition, the following growth factors are prohibited

Fibroblast Growth Factors (FGFs), Hepatocyte Growth Factor (HGF), Mechano Growth Factors (MGFs), Platelet-Derived Growth Factor (PDGF), Vascular-Endothelial Growth Factor (VEGF) as well as any other growth factor affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilisation, regenerative capacity or fibre type switching;

and other substances with similar chemical structure or similar biological effect(s).

S3. Beta-2 agonists

All beta-2 agonists, including all optical isomers (e.g. *d*- and *l*-) where relevant, are prohibited except inhaled salbutamol (maximum 1600 micrograms over 24 hours), inhaled formoterol (maximum delivered dose 54 micrograms over 24 hours) and salmeterol when taken by inhalation in accordance with the manufacturers' recommended therapeutic regime.

The presence in urine of salbutamol in excess of 1000 ng/mL or formoterol in excess of 40 ng/mL is presumed not to be an intended therapeutic use of the substance and will be considered as an *Adverse Analytical Finding* unless the *Athlete* proves, through a controlled pharmacokinetic study, that the abnormal result was the consequence of the use of the therapeutic inhaled dose up to the maximum indicated above.

S4. Hormone and metabolic modulators

The following are prohibited:

1. Aromatase inhibitors including, but not limited to: aminoglutethimide, anastrozole, androsta-1,4,6-triene-3,17-dione (androstatrienedione), 4-androstene-3,6,17 trione (6-oxo), exemestane, formestane, letrozole, testolactone.

2. Selective estrogen receptor modulators (SERMs) including, but not limited to: raloxifene, tamoxifen, toremifene.

3. Other anti-estrogenic substances including, but not limited to: clomiphene, cyclofenil, fulvestrant.

4. Agents modifying myostatin function(s) including, but not limited to: myostatin inhibitors.

5. Metabolic modulators:

a) Insulins

b) Peroxisome Proliferator Activated Receptor δ (PPAR δ) agonists (e.g. GW 1516), PPAR δ -AMP-activated protein kinase (AMPK) axis agonists (e.g. AICAR).

S5. Diuretics and other masking agents

Masking agents are prohibited. They include:

Diuretics, desmopressin, plasma expanders (e.g. glycerol; intravenous administration of albumin, dextran, hydroxyethyl starch and mannitol), probenecid; and other substances with similar biological effect(s). Local administration of felypressin in dental anaesthesia is not prohibited.

Diuretics include:

Acetazolamide, amiloride, bumetanide, canrenone, chlorthalidone, etacrynic acid, furosemide, indapamide, metolazone, spironolactone, thiazides (e.g. bendroflumethiazide, chlorothiazide, hydrochlorothiazide); triamterene, vaptans (e.g. tolvaptan); and other substances with a similar chemical structure or similar biological effect(s) (except drospirinone, pamabrom and topical dorzolamide and brinzolamide, which are not prohibited).

The use *In- and Out-of Competition*, as applicable, of any quantity of a substance subject to threshold limits (i.e. formoterol, salbutamol, cathine, ephedrine, methylephedrine and pseudoephedrine) in conjunction with a diuretic or other masking agent requires the deliverance of a specific Therapeutic Use Exemption for that substance in addition to the one granted for the diuretic or other masking agent.

Prohibited methods

M1. Manipulation of blood and blood components

The following are prohibited:

1. The administration or reintroduction of any quantity of autologous, allogenic (homologous) or heterologous blood or red blood cell products of any origin into the circulatory system.
2. Artificially enhancing the uptake, transport or delivery of oxygen, including, but not limited to, perfluorochemicals, efaproxiral (RSR13) and modified haemoglobin products (e.g. haemoglobin-based blood substitutes, microencapsulated haemoglobin products), excluding supplemental oxygen.
3. Any form of intravascular manipulation of the blood or blood components by physical or chemical means.

M2. Chemical and physical manipulation

The following are prohibited:

1. *Tampering*, or attempting to tamper, in order to alter the integrity and validity of *Samples* collected during *Doping Control*. These include but are not limited to urine substitution and/or adulteration (e.g. proteases).

2. Intravenous infusions and/or injections of more than 50 mL per 6 hours period except for those legitimately received in the course of hospital admissions or clinical investigations.

M3. Gene doping

The following, with the potential to enhance sport performance, are prohibited:

1. The transfer of polymers of nucleic acids or nucleic acid analogues;
2. The use of normal or genetically modified cells.

Substances and methods prohibited in-competition

In addition to the categories S0 to S5 and M1 to M3 defined above, the following categories are prohibited *In-Competition*:

Prohibited substances

S6. Stimulants

All stimulants, including all optical isomers (e.g. *d*- and *l*-) where relevant, are prohibited, except imidazole derivatives for topical use and those stimulants included in the 2014 Monitoring Program⁴.

Stimulants include:

a. Non Specified Stimulants:

Adrafinil; amfepramone; amphetamine; amfetaminil; amiphenazole; benfluorex; benzylpiperazine; bromantan; clobenzorex; cocaine; cropropamide; crotetamide; fencamine; fenetylline; fenfluramine; fenproporex; fonturacetam [4-phenylpiracetam (carphedon)]; furfenorex; mefenorex; mephentermine; mesocarb; metamfetamine(*d*-); *p*-methylamphetamine; modafinil; norfenfluramine; phendimetrazine; phenmetrazine; phentermine; prenylamine; prolintane.

A stimulant not expressly listed in this section is a Specified Substance.

b. Specified Stimulants (examples):

Benzfetamine; cathine⁵; cathinone and its analogues (e.g. mephedrone, methedrone, α -pyrrolidinovalerophenone); dimethylampheta-

⁴ The following substances included in the 2014 Monitoring Program (bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine, pipradol, synephrine) are not considered as *Prohibited Substances*.

⁵ Cathine is prohibited when its concentration in urine is greater than 5 micrograms per milliliter.

mine; ephedrine⁶⁾; epinephrine⁷⁾ (adrenaline); etamivan; etilamfetamine; etilefrine; famprofazone; fenbutrazate; fencamfamin; heptaminol; hydroxyamfetamine (parahydroamphetamine); isometheptene; levmetamfetamine; meclofenoxate; methylenedioxyamphetamine; methylephedrine⁸⁾; methylhexaneamine (dimethylpentylamine); methylphenidate; nikethamide; norfenefrine; octopamine; oxilofrine (methylsynephrine); pemoline; pentetrazol; phenpromethamine; propylhexedrine; pseudoephedrine⁹⁾; selegiline; sibutramine; strychnine; tenamfetamine (methylenedioxyamphetamine); trimetazidine; tuaminoheptane; and other substances with a similar chemical structure or similar biological effect(s).

S7. Narcotics

The following are prohibited:

Buprenorphine, dextromoramide, diamorphine (heroin), fentanyl and its derivatives, hydromorphone, methadone, morphine, oxycodone, oxymorphone, pentazocine, pethidine.

S8. Cannabinoids

Natural (e.g. cannabis, hashish, marijuana) or synthetic delta 9-tetrahydrocannabinol (THC) and cannabimimetics (e.g. "Spice", JWH018, JWH073, HU-210) are prohibited.

S9. Glucocorticosteroids

All glucocorticosteroids are prohibited when administered by oral, intravenous, intramuscular or rectal routes.

⁶⁾ Each of ephedrine and methylephedrine is prohibited when its concentration in urine is greater than 10 micrograms per milliliter.

⁷⁾ Local administration (e.g. nasal, ophthalmologic) of epinephrine (adrenaline) or co-administration with local anaesthetic agents is not prohibited.

⁸⁾ Each of ephedrine and methylephedrine is prohibited when its concentration in urine is greater than 10 micrograms per milliliter.

⁹⁾ Pseudoephedrine is prohibited when its concentration in urine is greater than 150 micrograms per milliliter.

Substances prohibited in particular sports

P1. Alcohol

Alcohol (ethanol) is prohibited *In-Competition* only, in the following sports. Detection will be conducted by analysis of breath and/or blood. The doping violation threshold is equivalent to a blood alcohol concentration of 0.10 g/L.

- Air Sports (FAI)
- Archery (WA)
- Automobile (FIA)
- Karate (WKF)
- Motorcycling (FIM)
- Powerboating (UIM)

P2. Beta-blockers

Unless otherwise specified, beta-blockers are prohibited *In-Competition* only, in the following sports.

- Archery (WA) (also prohibited *Out-of-Competition*)
- Automobile (FIA)
- Billiards (all disciplines) (WCBS)
- Darts (WDF)
- Golf (IGF)
- Shooting (ISSF, IPC) (also prohibited *Out-of-Competition*)
- Skiing/Snowboarding (FIS) in ski jumping, freestyle aerials/halfpipe and snowboard halfpipe/big air

Beta-blockers include, but are not limited to, the following:

Acebutolol, alprenolol, atenolol, betaxolol, bisoprolol, bunolol, carteolol, carvedilol, celiprolol, esmolol, labetalol, levobunolol, metipranolol, metoprolol, nadolol, oxprenolol, pindolol, propranolol, sotalol, timolol.

C. VERTALING

Zie *Trb.* 1991, 8.

In dat Tractatenblad dienen in de vertaling de volgende correcties te worden aangebracht.

Op blz. 37, in artikel 5, tweede lid, aanhef, dient het woord „laboratoria” te worden vervangen door „laboratoria”.

Op blz. 38, in artikel 6, tweede lid, vijfde regel, dient de zinsnede „de individu” te worden vervangen door „het individu”.

D. PARLEMENT

Zie *Trb.* 1995, 114.

E. PARTIJGEGEVENS

Zie *Trb.* 1991, 8, rubriek F en rubriek H van *Trb.* 1995, 114 en, laatstelijk, *Trb.* 2014, 21.

G. INWERKINGTREDING

Zie *Trb.* 1991, 8, *Trb.* 1995, 114, rubriek J van *Trb.* 1996, 284, *Trb.* 1997, 244, *Trb.* 1998, 104, *Trb.* 2001, 98, *Trb.* 2001, 185, *Trb.* 2003, 40 en *Trb.* 2004, 194, en rubriek G van *Trb.* 2005, 67, *Trb.* 2006, 33, *Trb.* 2008, 83, *Trb.* 2009, 24, *Trb.* 2010, 80, *Trb.* 2011, 19, *Trb.* 2011, 274, *Trb.* 2012, 243 en *Trb.* 2014, 21.

De wijziging van 7 mei 2014 van de Bijlage bij de Overeenkomst zal op 1 september 2014 in werking treden voor alle partijen bij de Overeenkomst, waaronder het Koninkrijk der Nederlanden.

Wat betreft het Koninkrijk der Nederlanden, zal de wijziging van de Bijlage, evenals de Overeenkomst, voor Nederland (het Europese en het Caribische deel), Curaçao en Sint-Maarten gelden.

J. VERWIJZINGEN

Zie *Trb.* 1991, 8, *Trb.* 1995, 114, *Trb.* 1996, 284, *Trb.* 1997, 44, *Trb.* 2004, 194, *Trb.* 2006, 33, *Trb.* 2008, 83, *Trb.* 2009, 24, *Trb.* 2010, 80, *Trb.* 2011, 274, *Trb.* 2012, 243 en *Trb.* 2014, 21.

Verbanden

Titel : Internationaal Verdrag tegen doping in de sport;
Parijs, 19 oktober 2005
Laatste *Trb.* : *Trb.* 2014, 92

In overeenstemming met artikel 19, tweede lid, van de Rijkswet goedkeuring en bekendmaking verdragen heeft de Minister van Buitenlandse Zaken bepaald dat de wijziging van de Bijlage van 7 mei 2014 zal zijn bekendgemaakt in Nederland (het Europese en het Caribische deel),

Curaçao en Sint Maarten op de dag na de datum van uitgifte van dit Tractatenblad.

Uitgegeven de *vijfentwintigste* augustus 2014.

De Minister van Buitenlandse Zaken,

F.C.G.M. TIMMERMANS